1. Signaling Pathways
  2. Anti-infection
  3. EBV


Epstein-Barr Virus

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives. EBV spreads most commonly through bodily fluids, primarily saliva. Primary EBV infection is usually asymptomatic and for many occurs during childhood, but when it occurs in adolescence or adulthood, 30%–50% cases manifest clinically as infectious mononucleosis (IM). EBV also cause infectious mononucleosis (IM), Burkitt lymphoma (BL), nasopharyngeal carcinoma (NPC), Hodgkin’s disease, and other illnesses. Many people become infected with EBV in childhood. EBV infections in children usually do not cause symptoms, or the symptoms are not distinguishable from other mild, brief childhood illnesses.

EBV Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-131236
    EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC50 value of 23 μM. EBNA1-IN-SC7 is used in EBV (Epstein-Barr virus)-related cancer research.
  • HY-119098
    Inhibitor 99.76%
    GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes.
  • HY-N11020
    Cabenoside D
    Cabenoside D (compound 8) is a triterpenoid glycoside, which can be isolated from the methanol extract of lichen root. Cabenoside D shows anti-inflammatory activity and inhibits inflammation induced by 12-O-tetracylacyl hormone-13-acetate (TPA) in mice. Cabenoside D also inhibits TPA-induced Epstein-Barr virus (EBV) early antigen (EBV-EA) activation.
  • HY-P1890
    CEF14, EBV Rta Protein (28-37)
    CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).
  • HY-105070
    Eritoran is a Toll-like receptor 4 (TLR4) antagonist. Eritoran protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran inhibits pathogenesis of filovirus infection.
  • HY-125471
    VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research.
  • HY-N11009
    11-Oxomogroside II A1
    11-Oxomogroside II A1 (compound 7) is an oxidized cucurbitin. It can be isolated from the ethanol extract of Rohanberry fruit. 11-Oxomogroside II A1 inhibits the activation of Epstein-Barr virus (EBV) early antigen (EBV-EA) induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). 11-Oxomogroside II A1 also weakly inhibits the activation of (±)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.
  • HY-P1911
    CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156)
    CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 corresponding to amino acids 148-156 of the BRLF1 protein. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some Epstein-Barr virus (EBV) lytic gene promoters.
  • HY-148170
    L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC50 value of 0.03μM. L-I-OddU has low cytotoxicity with a CC50 value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis.
  • HY-P1920
    CEF19, Epstein-Barr Virus latent NA-3A (458-466)
    CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition.